XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Mar. 31, 2023
Feb. 28, 2023
May 17, 2022
Dec. 20, 2018
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Jan. 01, 2022
Interest income         $ 183,416 $ 64,827    
Outstanding principal balance $ 781,958       781,958      
Accrued interest 53,445       53,445   $ 275,547  
Accounts payable balance 787,251       787,251   205,360  
Accounts receivable balance 22,561,797       22,561,797   22,761,990  
Revenue         12,349,777 13,071,800    
Grigorios Siokas [Member]                
Borrowing       $ 1,718,400        
Outstanding principal balance 13,029       13,029   12,821  
Foreign curreny translation         208      
Accrued interest 24,887       24,887   206,355  
Interest rate       4.70%        
Maturity date       Mar. 18, 2019        
Dimitrios Goulielmos [Member]                
Outstanding principal balance 11,089       11,089   10,912  
Loss 177              
Panagiotis Kozaris [Member]                
Shares owned         51,159 0    
Prepaid expenses 194,215       194,215   143,056  
DOC Pharma S.A. [Member]                
Interest income         59,796      
Prepaid expenses         $ 7,599,545      
Interest rate         5.50%      
Accounts payable balance 8,882       $ 8,882   201,991  
Accounts receivable balance 1,886,890       1,886,890   2,070,570  
Prepaid balance 4,940,863       4,940,863   3,320,345 $ 4,279,200
Revenue         $ 627 383,688    
Agreement term         5 years      
Pieces per product         1,000 pieces      
Loan current portion 446,187       $ 446,187   427,720  
Loan non-current portion 3,902,613       3,902,613   3,851,280  
Inventroy purchase 450,911       450,911   687,382  
Description of research and development     Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought in total as of December 31, 2022, 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost          
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                
Inventroy purchase 401,786       401,786   517,566  
Maria Kozari [Member]                
Accounts receivable balance $ 867,866       867,866   $ 760,025  
Net sales         $ 118,987 $ 113,621    
Cana Holdings Laboratories Holding Limited [Member]                
Secured promissory note   $ 4,457,520            
Description related to interest on principal   Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (4.77% as of March 31, 2023)            
Maturity of promissory note   5 years            
Interest income   $ 36,497